Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Endocyte, Inc., a biotech company developing guided therapeutics and diagnostics for personalized medicine, has announced that an independent data safety monitoring board (DSMB) recommended that enrollment into the PRECEDENT study continue.

4 Mar 2010

Older women with suspected ovarian cancer 'face referral delays'

Older women with suspected ovarian cancer are often not referred for investigation as quickly as younger women, new research suggests.

4 Mar 2010

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today it received a Notice of Allowance on monoclonal antibody ICT-69 which targets multiple myeloma and ovarian cancers. The antibody has demonstrated high specificity to these cancers by targeting a novel cell surface antigen.

2 Mar 2010

Supercomputer receives powerful supercomputer for biomedical and life sciences research from IBM

Rice University and IBM today unveiled a new high-performance computing initiative for biomedical and life sciences research that features one of the most powerful supercomputers in the Texas Medical Center. Rice scientists will use the supercomputer in collaboration with researchers from across the medical center to study cancer, AIDS and other complex diseases.

2 Mar 2010

Foster Friess to make substantial contribution to fund ovarian cancer research at TGen

Moved by the death of an employee's daughter, prominent international businessman and philanthropist Foster Friess will make a substantial contribution to fund ovarian cancer research at the Translational Genomics Research Institute.

2 Mar 2010

Study evaluates possible diet associations with ovarian cancer survival

2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease. Often diagnosed in late stages, ovarian cancer has an asymptomatic onset and a relatively low 5-year survival rate of about 45%. Consequently investigation linked to survivorship is critical.

1 Mar 2010

MDB Capital Group selects Health Discovery as one of Top 50 “Best and Brightest” companies

Health Discovery Corporation announced today it has been selected by MDB Capital Group as one of its Top 50 “Best and Brightest” companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.

27 Feb 2010

Fact-checks of the bipartisan health care summit

News outlets fact-check the bipartisan health care summit and provide analyses of the messaging and poll numbers lawmakers used during the six-hour event.

27 Feb 2010

Nanotechnology to tackle side effects and drug resistance in treatment of cancer

Huixin He, associate professor, nanoscale chemistry at Rutgers University, Newark, and Tamara Minko, professor at the Rutgers Ernest Mario School of Pharmacy, have developed a nanotechnology approach that potentially could eliminate the problems of side effects and drug resistance in the treatment of cancer. Under traditional chemotherapy, cancer cells, like bacteria, can develop resistance to drug therapy, leading to a relapse of the disease.

26 Feb 2010

NCCN Guidelines: Chemosensitivity/resistance assays to be part of Principles of Chemotherapy section

Precision Therapeutics announced today that The National Comprehensive Cancer Network® recently updated the NCCN Clinical Practice Guidelines for Oncology for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of chemosensitivity/resistance assays as part of the Principles of Chemotherapy section.

26 Feb 2010

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Manhattan Scientifics Inc., a nanomedicine technology transfer and commercialization pioneer, today announced completion of its agreement to acquire all commercial rights to the body of work of nuclear physicist Edward R. Flynn, PhD and his company, Senior Scientific LLC.

26 Feb 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed trial results are expected to be presented via appropriate scientific venue later this year.

24 Feb 2010

Unique resource for families facing hereditary breast and ovarian cancer

When she was forty-two, Joi Morris learned that she has a genetic mutation on a gene known as BRCA2. This meant that her risk of getting breast cancer could be as high as 84 percent by age seventy, and that her risk for ovarian cancer was also high.

23 Feb 2010

Researchers adopt new technique to inhibit cancer growth

One of the difficulties of fighting cancer is that drugs often hit other non-cancerous cells, causing patients to get sick. But what if researchers could sneak cancer-fighting particles into just the cancer cells?

17 Feb 2010

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

EntreMed, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the Company's lead oncology drug candidate, ENMD-2076, for the treatment of acute myeloid leukemia (AML).

16 Feb 2010

CTI reports financial results for fourth-quarter and year ended December 31, 2009

Cell Therapeutics, Inc. (CTI) today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2009.

11 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Biology of lung cancer varies by age and gender

The biology of lung cancer differs from one patient to the next, depending on age and sex, according to scientists at Duke University Medical Center. The findings may help explain why certain groups of patients do better than others, even though they appear to have the same disease.

10 Feb 2010

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Endocyte's PRECEDENT study: DSMB recommends enrollment to continue

Older women with suspected ovarian cancer 'face referral delays'

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

Supercomputer receives powerful supercomputer for biomedical and life sciences research from IBM

Foster Friess to make substantial contribution to fund ovarian cancer research at TGen

Study evaluates possible diet associations with ovarian cancer survival

MDB Capital Group selects Health Discovery as one of Top 50 “Best and Brightest” companies

Fact-checks of the bipartisan health care summit

Nanotechnology to tackle side effects and drug resistance in treatment of cancer

NCCN Guidelines: Chemosensitivity/resistance assays to be part of Principles of Chemotherapy section

Manhattan Scientifics completes agreement to acquire all commercial rights to Senior Scientific

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint

Unique resource for families facing hereditary breast and ovarian cancer

Researchers adopt new technique to inhibit cancer growth

EntreMed's ENMD-2076 for AML receives FDA's orphan drug designation

CTI reports financial results for fourth-quarter and year ended December 31, 2009

Medicinal chemistry paper related to the discovery of CUDC-101 published

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Biology of lung cancer varies by age and gender

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in